These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 33237699)

  • 1. Successful treatment of adalimumab-resistant palmoplantar pustulosis with secukinumab: a case report.
    Li QY; Wang G
    Chin Med J (Engl); 2020 Nov; 133(24):3013-3014. PubMed ID: 33237699
    [No Abstract]   [Full Text] [Related]  

  • 2. Successful treatment of secukinumab-resistant palmoplantar pustulosis by Dupilumab: A case report.
    Zheng YX; Zheng M; Cai SQ
    Dermatol Ther; 2022 Nov; 35(11):e15781. PubMed ID: 35986706
    [No Abstract]   [Full Text] [Related]  

  • 3. Successful treatment with secukinumab in a patient with generalized pustular psoriasis preceded by palmoplantar lesions.
    Sawai N; Kawakami Y; Tachibana K; Nomura H; Miyake T; Yokoyama E; Hirai Y; Morizane S
    J Dermatol; 2023 Dec; 50(12):e413-e414. PubMed ID: 37577828
    [No Abstract]   [Full Text] [Related]  

  • 4. Rapid therapeutic response of palmoplantar pustulosis under biologic treatment with guselkumab.
    Duderstadt S; Raap U; Patsinakidis N
    Dermatol Ther; 2021 Mar; 34(2):e14792. PubMed ID: 33480136
    [No Abstract]   [Full Text] [Related]  

  • 5. Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients.
    Wollina U; Hansel G; Koch A; Schönlebe J; Köstler E; Haroske G
    Am J Clin Dermatol; 2008; 9(1):1-14. PubMed ID: 18092839
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful Use of Tildrakizumab for Treatment of Palmoplantar Pustulosis: A Case Report.
    Del Campo DC
    J Drugs Dermatol; 2021 Oct; 20(10):1117-1119. PubMed ID: 34636515
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of adalimumab and secukinumab on comorbidities associated with metabolism in patients with plaque psoriasis.
    Zhang S; Cai L; Zhang H; Zhao Z; Liu X; Zhao Y; Zhang J
    Chin Med J (Engl); 2022 Sep; 135(18):2248-2250. PubMed ID: 35838381
    [No Abstract]   [Full Text] [Related]  

  • 8. The Efficacy of Biologic Therapy for the Management of Palmoplantar Psoriasis and Palmoplantar Pustulosis: A Systematic Review.
    Sanchez IM; Sorenson E; Levin E; Liao W
    Dermatol Ther (Heidelb); 2017 Dec; 7(4):425-446. PubMed ID: 29143230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Palmoplantar pustulosis emerged on a case of generalized pustular psoriasis successfully treated by secukinumab.
    Honma M; Nozaki H; Hayashi K; Iinuma S; Ishida-Yamamoto A
    J Dermatol; 2019 Dec; 46(12):e468-e469. PubMed ID: 31502309
    [No Abstract]   [Full Text] [Related]  

  • 10. Occurrence of palmoplantar pustulosis during atezolizumab therapy for non-small cell lung cancer.
    Onishi Y; Arakawa Y; Tamagawa-Mineoka R; Ohshita A; Masuda K; Katoh N
    J Dermatol; 2021 Nov; 48(11):e570-e571. PubMed ID: 34486162
    [No Abstract]   [Full Text] [Related]  

  • 11. Adalimumab treatment for acrodermatitis continua of Hallopeau: three cases refractory to IL-17 inhibition.
    Zhang Z; Wu X; Han C; Chen M; Liu Y
    J Dtsch Dermatol Ges; 2023 Jul; 21(7):785-787. PubMed ID: 37186059
    [No Abstract]   [Full Text] [Related]  

  • 12. Palmoplantar pustulosis under secukinumab in two patients without psoriasis.
    Penalba-Torres M; Rivera-Díaz R
    J Dtsch Dermatol Ges; 2022 Jan; 20(1):106-109. PubMed ID: 34751502
    [No Abstract]   [Full Text] [Related]  

  • 13. First emergence of pyoderma gangraenosum, palmoplantar pustulosis and sacroiliitis in a psoriasis patient associated with switching from secukinumab to brodalumab.
    Sadik CD; Thieme M; Zillikens D; Terheyden P
    J Eur Acad Dermatol Venereol; 2019 Nov; 33(11):e406-e407. PubMed ID: 31131924
    [No Abstract]   [Full Text] [Related]  

  • 14. Paradoxical nail psoriasis induced by the IL-17A inhibitor ixekizumab in palmoplantar pustulosis.
    André R; Boehncke WH; Laffitte E
    Int J Dermatol; 2023 Jul; 62(7):e370-e371. PubMed ID: 37057631
    [No Abstract]   [Full Text] [Related]  

  • 15. Successful effect of tocilizumab in anti-TNF-α-induced palmoplantar pustulosis in rheumatoid arthritis.
    Rueda-Gotor J; González-Gay MA; Blanco Alonso R; Gonzalez-Vela C; Lopez-Obregon C; González-López MA
    Joint Bone Spine; 2012 Oct; 79(5):510-3. PubMed ID: 22857979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR).
    Yiu ZZN; Mason KJ; Hampton PJ; Reynolds NJ; Smith CH; Lunt M; Griffiths CEM; Warren RB;
    Br J Dermatol; 2020 Aug; 183(2):294-302. PubMed ID: 32124442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Secukinumab is effective in the treatment of recalcitrant palmoplantar psoriasis and palmoplantar pustular psoriasis in a daily practice setting.
    Reolid A; Armesto S; Sahuquillo-Torralba A; Torres T; Feltes R; Vilarrasa E; Belinchón I; Cueva P; Rodríguez L; Romero-Maté A; Vidal D; Coto-Segura P; Herrera-Acosta E; Riera-Monroig J; Salgado L; Llamas-Velasco M; Daudén E
    J Am Acad Dermatol; 2022 Sep; 87(3):705-709. PubMed ID: 35640798
    [No Abstract]   [Full Text] [Related]  

  • 18. Serum C-reactive protein to albumin ratio as a novel inflammation biomarker in psoriasis patients treated with adalimumab, ustekinumab, infliximab, and secukinumab: a retrospective study.
    Tamer F; Avcı E
    Croat Med J; 2020 Aug; 61(4):333-337. PubMed ID: 32881431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Secukinumab-induced palmar vesiculopustular eruption in a patient with psoriasis.
    Satoh M; Yamamoto T
    Dermatol Ther; 2020 May; 33(3):e13332. PubMed ID: 32219955
    [No Abstract]   [Full Text] [Related]  

  • 20. Real world data from the use of secukinumab in the treatment of moderate-to-severe psoriasis, including scalp and palmoplantar psoriasis: A 104-week clinical study.
    Rompoti N; Katsimbri P; Kokkalis G; Boumpas D; Ikonomidis I; Theodoropoulos K; Rigopoulos D; Papadavid E
    Dermatol Ther; 2019 Sep; 32(5):e13006. PubMed ID: 31228319
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.